Informazione:
Errore:
ID
34300
Descrizione
A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis; ODM derived from: https://clinicaltrials.gov/show/NCT01166282
collegamento
https://clinicaltrials.gov/show/NCT01166282
Keywords
versioni (1)
- 16/01/19 16/01/19 -
Titolare del copyright
see on clinicaltrials.gov
Caricato su
16 gennaio 2019
DOI
Per favore, per richiedere un accesso.
Licenza
Creative Commons BY 4.0
Commenti del modello :
Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.
Commenti del gruppo di articoli per :
Commenti dell'articolo per :
Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.
Eligibility Enthesitis Related Arthritis (ERA) NCT01166282
Eligibility Enthesitis Related Arthritis (ERA) NCT01166282
- StudyEvent: Eligibility
Similar models
Eligibility Enthesitis Related Arthritis (ERA) NCT01166282
- StudyEvent: Eligibility
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
ID.1
Item
diagnosis of enthesitis related arthritis (era) as defined by international league of associations for rheumatology (ilar);
boolean
ID.2
Item
disease activity defined as at least 3 active joints and evidence of enthesitis in at least one location;
boolean
ID.3
Item
inadequate response or intolerance to at least one nonsteroidal anti-inflammatory drug and at least one disease modifying anti-rheumatic drug, either sulfasalazine or methotrexate.
boolean
ID.4
Item
any ilar juvenile idiopathic arthritis (jia) subtype other than era;
boolean
ID.5
Item
psoriasis or a history of psoriasis in the patient or first-degree relative;
boolean
ID.6
Item
presence of immunoglobulin m (igm) rheumatoid factor;
boolean
ID.7
Item
presence of systemic jia,
boolean
ID.8
Item
history of inflammatory bowel disease, previous biologic therapy including anti-tnf therapy with a potential impact on pediatric era;
boolean
ID.9
Item
infection(s) requiring treatment with iv anti-infectives within 30 days prior to baseline or oral anti-infectives within 14 days prior to baseline
boolean